CompletedNCT02139111
PRC-063 Compared With Placebo for ADHD in Adolescents
About this title
Read the official source — NCT02139111Medication studyAges 12–17United States + Canada
Understand this study
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Los Angeles and 42 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 360
- Sponsor
- Rhodes Pharmaceuticals, L.P.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT02139111
- Official title
Show the full official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles, United States · National City, United States · Newport Beach, United States
36 more locations
- Orange, United States
- Bradenton, United States
- Gainesville, United States
- Jacksonville, United States
- Maitlin, United States
- Orlando, United States
- South Miami, United States
- Tampa, United States
- Boise, United States
- Baltimore, United States
- Las Vegas, United States
- Durham, United States
- Raleigh, United States
- Cincinnati, United States
- Oklahoma City, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- San Antonio, United States
- Clinton, United States
- Salt Lake City, United States
- Herndon, United States
- Friday Harbor, United States
- Kirkland, United States
- Calgary, Canada
- Edmonton, Canada
- Vancouver, Canada
- Dartmouth, Canada
- Hamilton, Canada
- Niagra Falls, Canada
- Ottawa, Canada
- Toronto, Canada
- Whitby, Canada
- Montreal, Canada
- Saskatoon, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Rhodes Pharmaceuticals, L.P.
Did this study involve medication?
Yes. The study involved medication, including Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg and PRC-063 85 mg.
Who was this study for?
Listed age limits: 12 years to 17 years.
